- Home
- EAD vs MIRM Comparison
EAD vs MIRM Comparison
Compare EAD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- MIRM
- Stock Information
- Founded
- EAD 2003
- MIRM 2018
- Country
- EAD United States
- MIRM United States
- Employees
- EAD N/A
- MIRM N/A
- Industry
- EAD Finance/Investors Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- EAD Finance
- MIRM Health Care
- Exchange
- EAD Nasdaq
- MIRM Nasdaq
- Market Cap
- EAD 406.6M
- MIRM 2.5B
- IPO Year
- EAD N/A
- MIRM 2019
- Fundamental
- Price
- EAD $7.04
- MIRM $51.15
- Analyst Decision
- EAD
- MIRM Strong Buy
- Analyst Count
- EAD 0
- MIRM 9
- Target Price
- EAD N/A
- MIRM $66.22
- AVG Volume (30 Days)
- EAD 178.9K
- MIRM 444.2K
- Earning Date
- EAD 01-01-0001
- MIRM 08-06-2025
- Dividend Yield
- EAD 8.91%
- MIRM N/A
- EPS Growth
- EAD N/A
- MIRM N/A
- EPS
- EAD N/A
- MIRM N/A
- Revenue
- EAD N/A
- MIRM $379,251,000.00
- Revenue This Year
- EAD N/A
- MIRM $35.83
- Revenue Next Year
- EAD N/A
- MIRM $16.83
- P/E Ratio
- EAD N/A
- MIRM N/A
- Revenue Growth
- EAD N/A
- MIRM 69.31
- 52 Week Low
- EAD $5.69
- MIRM $33.45
- 52 Week High
- EAD $6.81
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- EAD 69.30
- MIRM 66.21
- Support Level
- EAD $6.83
- MIRM $49.41
- Resistance Level
- EAD $6.89
- MIRM $51.15
- Average True Range (ATR)
- EAD 0.03
- MIRM 1.64
- MACD
- EAD 0.00
- MIRM 0.09
- Stochastic Oscillator
- EAD 96.88
- MIRM 84.22
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.